

### AGENDA

*All times listed are in EST*

#### Monday, February 22

- 11:00am-1:00pm Scientific Session 1: Novel influences on tumorigenesis and progression**  
Each talk will be followed by Live Q&A  
*Chair: A. Hunter Shain, University of California, San Francisco*
- 11:00-11:10 Opening Remarks**
- 11:10-11:45 Keynote Lecture**  
**William Kaelin, Jr.**, Professor of Medicine, Dana-Farber Cancer Institute  
*(Re)emerging principles of cancer therapy*
- 11:45-12:10 Hilary Coller**, Professor, Molecular, Cell and Developmental Biology, University of California, Los Angeles  
*Autophagy in the melanoma microenvironment*
- 12:10-12:35 David Lombard**, Associate Professor of Pathology, University of Michigan  
*Oncogenic role of the SIRT5 deacylase in melanoma*
- 12:35-1:00 Titia de Lange**, Leon Hess Professor, The Rockefeller University  
Marcin Imielinski, Assistant Professor, Weill Cornell Medical School – Q&A only  
*The role of telomere crisis in acral melanoma*
- 5:30-6:30pm Young Investigator Social Hour** *(by invitation only)*
- 6:30-7:30pm Poster Session 1**

#### Tuesday, February 23

- 9:30-10:30am Poster Session 2**
- 11:00am-1:00pm Scientific Session 2: Novel immunotherapy targets and mechanisms of immune-related adverse events**  
Each talk will be followed by Live Q&A  
*Chair: Stefani Spranger, MIT*
- 11:00-11:05 Opening Remarks**
- 11:05-11:40 Keynote Lecture:**  
**Jennifer Wargo**, Professor, University of Texas MD Anderson Cancer Center  
*Understanding responses to cancer therapy: The tissue is the issue, the scoop is in the poop, and you are what you eat*

- 11:40-12:05** **Pan Zheng**, Professor of Surgery, University of Maryland, Baltimore  
*CTLA-4 lysosomal degradation governs the immune-related adverse events in anti-CTLA4 antibody immunotherapy*
- 12:05-12:30** **John Wilson**, Assistant Professor, Vanderbilt University  
*Engineering smart technologies for immuno-oncology*
- 12:30-12:55** **Kai Wucherpfennig**, Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute  
*Molecular pathways of colon inflammation induced by cancer immunotherapy*
- 5:30-6:30pm** **Patient Advocate Social Hour – Sponsored by Mollie’s Fund** (*by invitation only*)
- 6:30-7:30pm** **Networking Roundtables Session 1**

### Wednesday, February 24

**9:30-10:30am** **Networking Roundtables Session 2**

**11:00am-1:00pm** **Scientific Session 3: New approaches to detecting and treating melanoma**

Each talk will be followed by Live Q&A  
*Chair: Ku-Lung (Ken) Hsu, University of Virginia*

11:00-11:05 Opening Remarks

**11:05-11:40** **Keynote Lecture:**

**Richard Marais**, Director, Cancer Research UK Manchester Institute  
*Genetic approaches to refining melanoma treatment*

**11:40-12:05** **Keiran Smalley**, Director, The Melanoma and Skin Cancers Center of Excellence, Moffitt Cancer Center

*Multi-omics approaches to define the landscape of acral melanoma*

**12:05-12:30** **Liz Patton**, Programme Leader MRC Human Genetics Unit, University of Edinburgh

*Transcriptional mechanisms that underlie developmental cell states in melanoma*

**12:30-12:55** **Allan Halpern**, Chief, Dermatology Service, Memorial Sloan Kettering Cancer Center

*Advances and controversies in the early detection of melanoma*

**1:30-2:30pm** **Moderated Panel Discussion – No patient left behind: Impact of the pandemic and new directions for clinical research in rare melanomas.** **Panelists:** Maryam Asgari, Massachusetts General Hospital; Steven Lemery, US Food and Drug Administration; Ned Sharpless, National Cancer Institute. **Moderator:** Elliott Sigal, MRA Board of Directors